Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review.

ABSTRACT:

Introduction

Anti-CD38-based therapy has become a backbone regimen for the treatment of multiple myeloma (MM), approved in first-, second-, and third-line settings. The effectiveness of anti-CD38-based retreatment after an initial relapse on previous anti-CD38-based therapy is unclear. Here we present the results of a systematic literature review investigating the clinical outcomes of anti-CD38-based retreatment in patients with relapsed/refractory MM.

Methods

Medline/Embase, congress publications, and other sources were searched (to December 8, 2023) for relevant articles in English and screened for eligibility criteria using the Population, Intervention, Comparator, Outcomes, Study Design (PICOS) framework, and data were then extracted for outcomes including progression-fr

SUBMITTER: Gay F 

PROVIDER: S-EPMC11938063 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature